ReviewTrends in pharmacological sciences2014
The pathophysiology and pharmacology of hepcidin.
Review in Trends in pharmacological sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Vitamin D Enteral Supplementation on Hepcidin Serum Levels and Transfusion Requirements in Surgical and Critically Ill Patients
The Correlation Between Anemia of Chronic Diseases, Hepcidin and Vitamin D in IBD Patients
Who cites it
65 citing papers in PubMed, 138 citations in OpenAlex.
- Association of Daily Dietary Intake and Inflammation Induced by Marathon Race.Mediators of inflammation · 2019Trial
- Serum hepcidin as a host-derived biomarker of disease severity and risk stratification in tuberculosis.Infection · 2026Article
- Hepcidin concentration and effect on iron homeostasis in patients with adrenocortical carcinoma and benign adrenal lesions - a pilot study.Endocrine · 2026Article
- Iron, the Essential Micronutrient: A Comprehensive Review of Regulatory Pathways of Iron Metabolism.Nutrients · 2025Review
- Serum Hepcidin as a Biomarker of Subclinical Atherosclerosis in Peritoneal Dialysis: A Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Targeting macro- and micro-nutrient regulation of HNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Epidemiology of inflammatory bowel disease-associated anemia in children and adolescents from 1990 to 2021: a global, regional analysis from the Global Burden of Disease Study.Frontiers in pediatrics · 2025Article
- The hepcidin-ferroportin axis influences mitochondrial function, proliferation, and migration in pulmonary artery endothelial and smooth muscle cells.Pulmonary circulation · 2024Article
- The Role of Iron Metabolism in Sepsis-associated Encephalopathy: a Potential Target.Molecular neurobiology · 2024Review
- Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.International journal of molecular sciences · 2023Review
- Iron Load Toxicity in Medicine: From Molecular and Cellular Aspects to Clinical Implications.International journal of molecular sciences · 2023Review
- Managing the Dual Nature of Iron to Preserve Health.International journal of molecular sciences · 2023Review
- Hepcidin and erythroferrone response to 3 weeks of exposure to normobaric hypoxia at rest in trained cyclists.Frontiers in physiology · 2023Article
- The first study on urinary loss of iron and transferrin in association with proteinuria in dogs with chronic kidney disease.Veterinary world · 2023Article
- Hyperferritinemia, Low Circulating Iron and Elevated Hepcidin May Negatively Impact Outcome in COVID-19 Patients: A Pilot Study.Antioxidants (Basel, Switzerland) · 2022Article
- Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases.Molecules (Basel, Switzerland) · 2022Review
- The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials.Annals of translational medicine · 2021Article
- Iron, Copper, and Zinc Homeostasis: Physiology, Physiopathology, and Nanomediated Applications.Nanomaterials (Basel, Switzerland) · 2021Review
- Iron metabolism in infections: Focus on COVID-19.Seminars in hematology · 2021Review
- Hepatocrinology.Medical sciences (Basel, Switzerland) · 2021Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Inappropriate production of the iron-regulatory hormone hepcidin contributes to the pathogenesis of common iron disorders. Absolute or relative deficiency of hepcidin causes iron overload in hereditary hemochromatosis and iron-loading anemias. Elevated hepcidin causes iron restriction in inflammatory conditions including autoimmune disease, critical illness, some cancers, and chronic kidney disease. Multiple agents targeting hepcidin and its regulators are under development as novel therapeutics for iron disorders. This review summarizes hepcidin biology and discusses the current landscape for hepcidin-targeting therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.